Skip to main content

Table 5 Literature data

From: Toxicity after radiochemotherapy for glioblastoma using temozolomide - a retrospective evaluation

Authors Number of patients Toxicity 3/4° leucocytes Toxicity 3/4°
thrombocytes
Remarks I Remarks II
Randomized trials
Athanassiou et al. 2005 [11] 130 3.5% 5.2% 1 pat. died of sepsis  
Stupp et al., 2005 [1] 573 4% 3% Severe infections in 3%  
Retrospective analyses
Armstrong 2008 [12] 203 Clinically significant lymphopenia in 45% of women and 6% of men Abstract  
Combs et al. 2005 [26] 53 2% 0 No severe late effects temozolomide 50 mg/m2
Combs et al. 2008 [14] 160 Hematologic toxicity
5% (50 mg/m2) vs. 14% (75 mg/m2)
Premature discontinuation 6.5% vs. 14% Comparison temozolomide 50 vs. 75 mg/m2
Fiorica et al. 2010 [15] 42 0 5%   
Gerber 2007 [16] 52 Neutro-penia
In 18%
15% Mean duration 332 days [1-389 days] 10% required platelet transfusions, 67% discontinued radiochemo-therapy
Gerstein et al. 2009 [17] 51 Hematologic toxicity
14%
Premature discontinuation in 41%  
Jeon 2009 [27] 79 Hematologic toxicity
7.5%
1 pat. with severe lung infection  
Kimple 2010 [19] 32 3% 0   
Minniti et al. 2008 [20] 32 3% 3% Pneumonia in 3%  
Our data 46 15% 17%   43% discontinued treatment